TY - JOUR
T1 - An update on anti-TNF agents in ulcerative colitis
AU - Samaan, Mark A.
AU - Bagi, Preet
AU - Vande Casteele, Niels
AU - D'Haens, Geert R.
AU - Levesque, Barrett G.
PY - 2014
Y1 - 2014
N2 - Anti-tumor necrosis factor-α agents are key therapeutic options for the treatment of ulcerative colitis. Their efficacy and safety have been shown in large randomized controlled trials. The key evidence gained from these trials of infliximab, adalimumab, and golimumab is reviewed along with their effect on mucosal healing and long-term outcomes. Also reviewed are methods for optimizing their effectiveness, including therapeutic drug monitoring and treat-to-target strategies. Finally, remaining unresolved questions regarding their role and effectiveness are considered including how these may be addressed in future clinical trials
AB - Anti-tumor necrosis factor-α agents are key therapeutic options for the treatment of ulcerative colitis. Their efficacy and safety have been shown in large randomized controlled trials. The key evidence gained from these trials of infliximab, adalimumab, and golimumab is reviewed along with their effect on mucosal healing and long-term outcomes. Also reviewed are methods for optimizing their effectiveness, including therapeutic drug monitoring and treat-to-target strategies. Finally, remaining unresolved questions regarding their role and effectiveness are considered including how these may be addressed in future clinical trials
U2 - https://doi.org/10.1016/j.gtc.2014.05.006
DO - https://doi.org/10.1016/j.gtc.2014.05.006
M3 - Article
C2 - 25110254
SN - 0889-8553
VL - 43
SP - 479
EP - 494
JO - Gastroenterology Clinics of North America
JF - Gastroenterology Clinics of North America
IS - 3
ER -